Status:
UNKNOWN
Rapid Improvement of Depression of Fluoxetine Combined With ATP
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The clinical study is a randomized (1:1:1), double-blind, placebo-controlled clinical study. Recruit patients with moderate to severe depression. After signing the informed consent, patients who meet ...
Eligibility Criteria
Inclusion
- Meet DSM-V diagnostic criteria for moderate to severe depression.
- HAMD-24 scores ≥ 20.
- 18-65 female or male.
- Subjects who have not used any antipsychotic drugs, antidepressants, mood stabilizers (sodium valproate, lithium carbonate) or fluoxetine treatment within the first month prior to the start of this study
- Written informed consent.
Exclusion
- Sufferring from various major mental disorders other than depression (such as bipolar disorder, schizophrenia, personality split, etc.).
- Individuals with neurological disorders such as dementia.
- Individuals with a high risk of suicide.
- Pregnant and lactating women.
- Individuals with alcohol or drug abuse or dependence within one year prior to the start of this study.
- Contraindications to MRI.
- Physician evaluation was not suitable for participants in this study.
Key Trial Info
Start Date :
January 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT05431413
Start Date
January 7 2020
End Date
December 30 2025
Last Update
November 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515